Plasma urate and progression of mild cognitive impairment.
Plasma urate and progression of mild cognitive impairment.
复制标题
DOI：
10.1159/000170883
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Aisen PS
中科院分区：
文献类型：
--
作者：
Irizarry MC;Raman R;Schwarzschild MA;Becerra LM;Thomas RG;Peterson RC;Ascherio A;Aisen PS
抗氧化防御受损与神经退行性疾病有关。阿尔茨海默病（AD）患者血浆中尿酸盐（一种水溶性抗氧化剂）水平降低。检验基线时高血浆尿酸盐与以下因素相关的假设：（1）轻度认知功能障碍（MCI）向AD的转化率降低和（2）MCI中认知功能下降率降低。在一项为期三年的、随机、双盲、安慰剂对照的多奈哌齐、维生素E或安慰剂延迟MCI进展为AD的研究中，从747名参与者中获得基线血浆尿酸盐。通过考克斯比例风险回归检查基线尿酸盐与从MCI转变为AD之间的关联。通过纵向分析研究基线尿酸水平与阿尔茨海默病评估量表（ADAS-cog）认知子量表中认知变化的关系。基线血浆尿酸盐与MCI向AD的转化率无关。在安慰剂组中，高血浆尿酸盐与3年内认知能力下降速度较慢相关，尽管这在其他治疗组中没有重现。虽然血浆尿酸盐水平不能预测MCI向AD的进展，但高尿酸盐水平可能与未接受多奈哌齐或维生素E治疗的MCI患者的认知功能下降率降低有关。研究结果支持将抗氧化状态的生物标志物作为MCI认知功能下降的危险因素。
Impaired antioxidant defenses are implicated in neurodegenerative disease. Plasma levels of urate, a water soluble antioxidant, are reduced in Alzheimer's disease (AD). To test the hypotheses that high plasma urate at baseline is associated with: (1) reduced rate of conversion from mild cognitive impairment (MCI) to AD and (2) reduced rate of cognitive decline in MCI. Plasma urate was obtained at baseline from 747 participants in a three year, randomized, double-blind, placebo-controlled study of donepezil, vitamin E, or placebo for delaying progression of MCI to AD. The association between baseline urate and conversion from MCI to AD was examined by Cox proportional hazards regression. The association of baseline urate with cognitive change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) was examined by longitudinal analysis. Baseline plasma urate was not associated with rate of conversion of MCI to AD. In the placebo arm, high plasma urate was associated with a slower rate of cognitive decline over 3 years, although this was not reproduced in the other treatment arms. While plasma urate levels did not predict progression of MCI to AD, high urate may be associated with a reduce rate of cognitive decline in MCI patients not treated with donepezil or vitamin E. The results support investigation of biomarkers of antioxidant status as risk factors for cognitive decline in MCI.
登录
查看更多内容
影响因子：
158.5
作者：
Petersen, RC;Thomas, RG;Thal, LJ
通讯作者：
Thal, LJ
影响因子：
--
作者：
Schwarzschild, Michael A.;Schwid, Steven R.;Ascherio, Alberto
通讯作者：
Ascherio, Alberto
影响因子：
2.4
作者：
Schretlen, David J.;Inscore, Anjeli B.;Pearlson, Godfrey D.
通讯作者：
Pearlson, Godfrey D.
影响因子：
120.7
作者：
EVANS, DA;FUNKENSTEIN, H;TAYLOR, JO
通讯作者：
TAYLOR, JO
影响因子：
5
作者：
Davis, JW;Grandinetti, A;Morens, DM
通讯作者：
Morens, DM